Insoluble aggregates stainingp ositive to amyloid dyes are known histological hallmarks of different neurodegenerative disorders and of type II diabetes. Soluble oligomers are smaller assemblies whose formation prior to or concomitant with amyloid deposition has been associated to the processes of disease propagation and cell death. While the pathogenic mechanisms are complex and differ from disease to disease, both types of aggregates are important biological targets subjectt oi ntense investigation in academia and industry.H ere we review recent advances in the fundamental understandingo fp rotein aggregation that can be used on the development of anti-amyloid and antioligomerization drugs.S pecifically, we pinpoint the chemical kinetic aspects that should be attended during the development of high-throughput screening assays and in the hit validation phase. The strategies here devised are expectedt o establish ac onnection between basic research and pharmaceuticalinnovation.
Introduction
Over the recent years, protein aggregation has been in the limelighto fd rug discovery:o nt he one hand, severalp rojects targetinga myloid aggregates in neurodegeneratived isorders have been discontinued. [1] On the other hand, smaller protein aggregates-the soluble oligomers-are increasingly surfacing as major culpritso fn eurotoxicity and pathogenic spread. [2] Coincidently with this paradigm shift, [3] encouraging resultsh ave been obtained by the first generation of anti-oligomerization drug candidates in clinicalt rials of Alzheimer's disease and Parkinson's disease. [4] The long and costly workflow leading to the discovery of new drugs has in its basis methodso fh igh-throughput screening (HTS) of active compounds (known as "hits") that can be furtherd eveloped into drug precursors (knowna s" leads") or used as "chemical probes" to validate ag iven biological target. [5] Targeted HTS approaches rely on in vitro protein aggregation assays having well-definedr eaction components and high reproducibility indexes. [6] However,d eciphering the exact mode of action of aggregation inhibitors is not at rivial task on account of the possible pathways (Figure1a) and multiple elementarys teps (Figure 1b )t hat might be implicated. It may occur,f or instance, that large amounts of stable soluble oligomers are formed without their presence being directly detected by amyloid-specific probes sucha st hioflavin-T (ThT) or by turbidimetric methods. [7] Widely applied in the study of amyloid aggregation mechanisms, [10] chemical kinetic analysis is gradually being established as ap romising tool fort he systematic screenings of both anti-amyloid and anti-oligomerization compounds. [11] An important step in this direction was taken by definingt he referencek inetic behavior expected for generic nucleation-andgrowth processes of phase transition. [12] When no other pathway is present, the formation of insoluble species begins with the elementary step of primary nucleation and then proceeds through the occurrenceo ft he autocatalytics teps of secondary nucleation and growth. Thermodynamic equilibrium is attained when the chemical potential of thes olution equals that of the insoluble fraction.A tt hat point, the concentrationo fp rotein monomer (C)c orresponds to the protein solubility (C*), and so the driving force for phase transitionr epresented by supersa- Figure 1 . Aggregation pathways during amyloid fibril formation. a) Protein monomerse stablishathermodynamic equilibrium with solubleo ligomers that are either on-or off-pathwayt oproduce amyloid fibrils. Off-pathway oligomersc an undergo phase transition processes leadingt othe formation of different types of precipitates, [8] and then act as heterogeneous nucleants of amyloid fibrils. b) Reactionsteps participatingi nt he amyloid pathway. Green glowsr epresent an increase in the mass of amyloid fibrils. [9] [a] turation DC ¼ C À C* (or in dimensionless form s ¼ DC=C*)i s zero. After expressing supersaturation in terms of the normalized reaction conversion (a),
The following closed-form solution of the mass balance equations is obtained for unseeded reactions (a 0 ¼ 0): [12] a ¼ 1
where k a and k b are determined by the elementary steps that increaset he mass of insoluble aggregates (Figure 1b ). Sigmoidal progress curvesc omprising an initial lag phase followed by an exponential phase and ap lateau phase are expected in the cases of slow primary nucleation, [6, 13] for which the values of k b are lower than $ 0:01. [7, 12] In turn, fast primary nucleation processes (k b > 0:01) give rise to hyperbolic progress curves that are also observed during seededa ggregation assays (see section 2.). Protein aggregation modulators can be screened based on kinetic signaturesstanding out from the standard behavior expected by Equation (2). [7] This is valid for both onand off-pathway inhibition as it is shown next for the case of amyloidf ibril formation.
The Amyloid Aggregation Assay
Amyloidf ibrils have ac haracteristicc ross-beta-sheet structure that is detectable upon binding to Congo red, ThT and thiofla-vin-S (ThS) dyes. [11a, 14] Although amyloid aggregation can be followed by other spectrophotometric techniques, [15] thioflavin fluorescencei sa dequate for HTSk inetic assays that require low sample volume, high signal-to-noise ratios and high reproducibility. [6, 11b] The use of this probe is not without pitfalls arising from non-amyloid binding,r educed sensibility to early (onpathway) aggregates and fluorescences elf-quenching. [16] As with other assays employing light-basedd etection methods, orthogonal validation using different output reporters is required in order to identify false positivesa nd fluorescence artifacts. [17] The developmenta nd optimization of HTSa ssays aims at rightfully interrogate ag iven therapeutic target using miniaturizedf ormats of 96-well,3 84-well or 1536-well microplates. [18] Since amyloid nucleation is as tochastic process, [19] some variability between replicate experiments is expectable even when homogeneous, highly pure protein samples are used. [20] This is detrimental for the quality of the HTS assayu sually characterized in terms of the Z 0 factor (Figure 2a )t aking into account the means (m)a nd standard deviations (SD) of positive and negative controls. A Z 0 factor > 0:5i ndicates ag ood degree of separation between controls. [21] To improve reproducibility, pre-formed fibrils (or "seeds") can be added to the initial solution to bypass the primary nucleation step. [22] The drawback of seededa ssays is their insensibility to aggregation inhibitors specifically targeting non-templatedn ucleation. Other alternatives designed to accelerate fibrillationt hrough the use of glass beads, vigorousa gitation, high temperature, low pH and/ or denaturating additives only remotelyr eproduce the biological medium. [22] Heterogeneous nucleantss uch as lipid micelles, can be used to mimic the cell membrane and disease-propagating exosomes, [23] and at the same time catalyze protein aggregation with improved reproducibility. [24] In principle, seeding is not expected to influence the ThT fluorescencei ncrease (DF F ), which is an important thermodynamic measurable ( Figure 2a )p roportionalt ot he initial supersaturation DC 0 ¼ C 0 À C*.T he kinetic influence of seeding is accounted by analyzing the normalized progress curves ( Figure 2b )a nd the half-life coordinates t 50 and v 50 (Figure 2c ). The fundamental definitions of t 50 and v 50 are expressedi nt erms of apparent rate constants k 0 a and k 0 b , [12] 
which in turn are influencedb yt he initial fraction of seeds a 0 (computed in relation to the total polymerizable protein, DC 0 ):
For unseeded reactions
Asitfollows from eq 2, otherwises igmoidal progressc urves (k b < 0:01) will develop hyperbolic shapes if > 1% of preformed fibrils are added to the initial solution (k 0 b > 0:01).
Recognizable Modulators
Timely reviews on protein aggregation modulation were put forward by for example, Doig and Derreumaux, [25] Eisele et al., [26] and Velander et al., [27] where differentc lassifications of inhibitors are adoptedb ased on mechanistic and physicochemicalc onsiderations. Here we make as horter selection of examples that are representativeo ft he modes of action summarized in Figure 3 . For the sake of simplicity each mechanism is illustrated separately,a lthough synergistic and antagonistic effects may take place simultaneously.T he selected examples are listed in Table 1 .
Purely kinetic inhibitors ( Figure 3a )s low down the rate of fluorescencei ncrease without changing the final fluorescence, which is avalue indicative of the amountofamyloid fibrils produced. This is achieved through kinetic inhibition of any of the steps of primary nucleation, secondary nucleationo rfibril elongation thati ncrease the amyloid-specific signal (indicated by green arrows in Figures 1a nd 3) . Fluorination of the hydrophobic residues valine or phenylalanine of the LVFFD peptide increases the duration of the lag phaseo fA b42 aggregation without significantly changing the normalized aggregation rate v 50 or the value of the total fluorescencei ncrease F 1 . [28] Therefore, the fluorinated peptides are considered kinetic inhibitors acting upon the step of primary nucleation. [28] The lead compound CLR01 is am olecular tweezer that specifically binds to lysine residues thus disrupting important interactions for protein aggregation. [29] The impact of CLR01 on ThT progress curvesc hanges according to the amyloidogenic protein being studied;i nt he case of Ab40 aggregation, at enfold excessa dded during the exponentiala nd plateau phases induced an evident disaggregatinge ffect manifested by ap rogressive loss of amyloid signal. [30] Thist rend, which hasa lso been observedd uring incubation of Ab42 with brazilin, [31] corresponds to the kinetic signature of fibril disaggregators (Figure 3b) .
By preventing fragmentation, fibril stabilization ( Figure 3c ) might reduce prion-like spreading of small aggregates within and between cells, as demonstrated for seeded spreading of Ab and tau using animal modelso fA lzheimer's disease. [26, 32] Tight binding fibril stabilizers might also decrease the amyloid solubility and redirect the equilibrium from potentially more toxic, small oligomers to amyloid fibrils (large green arrow in Figure 3c ). [7, 8, 12] Thish ypothesis has been explored through the development of orange G-relatedc ompoundsb ound to the steric zipper Ab16-21 structure. [33] According to the supersaturation-dependence of k a and k b , protein-specific modulation of solubility (C*)i sa na ttractive approacht oc hange the kinetics-and not only the thermodynamics-ofa myloid fibril formation. This can be achieved using as targett he amyloid pharmacophore of the soluble protein ( Figure 3c )o r, alternatively, the metastable oligomers (Figures 3d,e ). Monomer stabilizers (Figure 3d )s electively increase the solubility of the target protein, shiftingt he on-and offpathway equilibria towards the dissociation of oligomers. As the result of the higher C* values, less amyloid fibrils are produced and lower fluorescences ignals are expecteda tt he end of the assay (Figure 3d (Figure3d, bottom) . Monomer stabilizers and oligomer binders ( Figure 3e )a re not clearly distinguishable from simple progress curvesa nalysis if the mode of action of the latter type of inhibitor comprises the stabilization of the oligomeric assembly.T his is because as the amyloidogenic protein is sequestered into the oligomeric state, the pool of available monomersi sd epleted leading to the train of events that culminates in lower DF 1 values and slower aggregation kinetics. Mimics of the islet amyloid polypeptide (IAPP) synthesized with N-methylated amide bonds were shown to inhibitt he aggregation of IAPP and Ab40 by acommonmechanism of stabilization of protein monomersa nd nontoxic oligomers. [34] Accordingly, the IAPP mimics are included in the categories of protein and oligomer stabilizers (Figures 3d,e, respectively) . The stabilization of the transthyretin (TTR) tetramer by tafamidis (Vyndaqel;P fizer), [35] and by the repurposed drugs diflunisal [36] and tolcapone [37] inhibits the formation of amyloid deposits by preventing the dissociation of the tetramer into aggregation competent TTR monomers. Commonly referred as "kinetic stabilizers', [26] thesec ompounds are here classified as oligomer stabilizers (Figure 3e )t oa void confusionw ith the kinetici nhibitors having no thermodynamic effects on aggregation (Figure 3a) .
The new evidences associating non-amyloidogenic oligomers to the pathogenesis of neurodegenerative diseases allow us to anticipate ar enewed interest in oligomer breakers (Figure 3e )a satherapeutic hypothesis to remodel toxic assemblies into nontoxic species. In the example of Figure 3e ,t he aggregation equilibrium is redirected to the formation of more amyloid fibrils (Figure 3e ,t op) and at faster rates (Figure 3e , bottom).O ther scenarios are, however,p ossible in which the amyloid pathway is not favored either because protein solubility is concomitantly increased or,a si nt he case of Ab42 aggregation in the presence of the N-methylated peptidei nhibitor SEN304, [38] other nontoxic pathways are elicited. Table 1 . Examples taken from the literature illustrating the different typesofa ggregation modulators presented in Figure 3 .
ModulatorR epresentative Examples
Kinetic Inhibitor -P eptide LVFFD with fluorinated valine or phenylalanine during Ab42 aggregation. [28] Disaggregator -C LR01 during Ab40 aggregation. [30] -B razilin duringA b42 aggregation. [31] Fibril Stabilizer-O rangeG -relatedc ompoundsbound to the steric zipper Ab16-21s tructure. [33] Monomer Stabilizer -M imics of IAPP synthesized with N-methylated amide bonds duringt he aggregation of IAPP and Ab40. [34] Oligomer Binder-T afamidis, [35] diflunisal [36] and tolcapone [37] during the aggregation of TTR.
-N-Methylated peptideinhibitorSEN304d uring the aggregation of Ab42. [38] Apparent Inhibitor-T hermodynamic effects provokedb yi nterfaces or by the additiono fs alts during amyloid aggregation. [42] Changing the ionic strength of amyloidogenic solutionsb y the addition (or removal)ofs alts can have adramatic influence on amyloid aggregation in vitro, [39] which is understood in terms of the role of solubility in determining the rate and extent of protein self-assembly. [7, 8, 12, 40] These modulation effects are considered "apparent" (Figure 3f )s incet hey are unspecific and tend to be buffered in cells and tissues media. Apparenti nhibitors that solely alter the activity coefficient of the protein will originate superimposed progress curvesi fr epresented in normalizedT hT fluorescenceu nits (Figure 3f , bottom); this has been previously illustrated using published data of Pronchik et al. [41] on the influence of hydrophobic interfaces on a-synuclein aggregation. [42] It should be noted that the superimposition of normalized curves does not necessarily imply that the test compound should be discarded. In fact, Figure 3d oes not exhaustively cover all possible mechanisms of inhibition, but insteadi ts eeks to summarize the major types of modulators that can be identified by kinetic assays.
Primary Screenings, Secondary Screenings, Hit Validation
Having set up ar eproducible amyloida ggregation assay does not guaranteet hat large numbers (> 10 5 )o fc hemical compounds can be efficiently assessed during HTS campaigns, especially if severald ays are requiredt om easuref ull progress curves. In these cases,aprimary screening strategy can be devised to limit the measurementf requency to the initial, middle, andf inal points of the reaction (Figure 4) . The corresponding values F 0 , F 50 and F F (Figure 4a )c an be followed in multiple plates simultaneouslyw ithouta dvanced robotic systems being necessarily required. Positive hits stand out by showing DF 50 =DF F ratios significantly differentf rom the value of 0.5 expected in the absence of modulation effects and for apparent inhibitors (Figure 4b) .
The 3-point aggregation assay can be used on the identification of positive hits as well as on the preliminaryc haracterization of the putative inhibition mechanism.T his requires the analysiso ft he DF 50 =DF F ratio (Figure 5a )b ut also of DF F valueso btained in the presence anda bsence of the test compound (Figure 5b ). Kinetic inhibitors, for example, are expected to originate values of DF 50 =DF F ( 0:5w ith no major impact on the values of DF F (Figure 5c ). The progress curvesc haracteristic of monomer and soluble oligomer stabilizers are not easily distinguishable (see previous representations in Figures 3d and 3e), and both are associated to markedly low values of DF 50 =DF F and of DF F (Figure 5d ). Conversely,v ery high valueso fDF 50 =DF F and of DF F mayi ndicate the cases of fibril stabilizers and of oligomer breakers (Figure 5e ).
In the same wayt hat Figure 3d id not cover all possible inhibition mechanisms, Figure 5g ives al imited number of examples that can be identified by the 3-point screening assay.A s expectable, this initial analysisi sn ot free from ambiguities as exemplified in Figure 5bycell B3, whose result can be ascribed Figure 4 . Ap ossible strategy for primary screeningsb ased on initial, midpoint and endpoint measurements. a) The midpoint(t 50 )a nd endpoint (t F ) instants are definedb eforehand taking into accountt he control progress curve (solid line) characterizing the amyloid aggregationa ssay. Rathert han continuously measuring the full progress curve in the presenceo ftestcompounds( dashed line), only the fluorescencei ncrease at time-points t 50 (DF 50 ¼ F 50 À F 0 )a nd t F (DF F ¼ F F À F 0 ), respectively,a re measured.b )Negative results elicited by,e.g.,f luorogenic compounds and apparenti nhibitors can be identified by valueso fthe DF 50 =DF F ratio close to 0.5. to fibril stabilizers, oligomer breakers (both cases represented in Figure 5e )o ru ndefined aggregations uppressors (Figure 5d ). To clarify this type of doubts, the initial hits-including the undefined results-havet ou ndergo the next round of screenings based on dose-response, full progress curve analysis.
In addition to the conventional representation of a over time, amyloid aggregation curvesa re conveniently plotted in log-linear a= 1 À a ðÞ vs. time coordinates so as to detect deviations from the standard behavior expected by Equation (2). These deviations, which are dealt in detail elsewhere, [7] are evidenced by non-linear trends arising after the initial lag phase. The relative importance of off-pathway aggregationg enerally increases as the curvature of the ln a= 1 À a ðÞ ðÞ representation gets more pronounced. Therefore, distinguishingb etweens imilar signatures of aggregation modulators such as fibril stabilizers and oligomer breakers (Figures 3c,e ), or monomer stabilizers and oligomer stabilizers (Figures 3d,e) is possible by representing the reactionc oordinates in the modified log-linear scale. Dose-response analyses of the assay measurables t 50 , v 50 and DF F are important to establish the potency of the selected compounds by means of the half-maximal inhibitory concentration (IC 50 )a nd the half-maximal effective concentration (EC 50 )p arameters. [44] Yet, to answer the questiono n whether the right target has been reached, the relationships DF F , v 50 ,a nd t 50 vs. protein concentration at constant compound concentration should also be looked in detail.I nr ecent contributions we demonstrated that these scalingl aws reflect the relative composition of monomers and soluble oligomers measured by direct methods. [9, 43] Specifically,adirect correspondence between the end-point amyloid signala nd the initial concentration of monomer can be expected when no offpathway oligomers are present ( Figure 6a )o rw hen their dissociation is much slower than the formation of amyloid fibrils (Figure 6b ). This correspondence will not be observed if the oligomerization equilibrium is reversed by the gradual vanishing of protein monomers provoked by the amyloidogenic pathway ( Figure 6c ). Examples of refractory and reversible offpathway oligomerization were observed during the aggregation of human insulin and ataxin-3, respectively. [9, 43] The oligomerization pathway can be further probed by analyzing the influence of protein concentration on the half-life coordinates.T he scalingl aws of v 50 (Figure 7a )a nd t 50 (Figure 7b )s how marked deviations from linearity in the presence of slowly dissociating oligomers, with unconventional scaling exponents(g)being admissible independently of the dominant step(s) of amyloid fibrillation (Figure 7b ). Within the context of HTS secondary screenings, the analysis of protein concentration scaling laws in the presence and absence of test compoundsi sa ne ffort worth making in order to discriminate which pathway is being affected and by which mechanisms.
Hit resultsf ound by indirect kinetic assays need to be validated by ac ombination of experimental methodsc apable of characterizing both quantitatively and qualitativelyt he target aggregates. The availableo ptions can be roughly categorized into spectroscopic, chromatographic, calorimetric, light scattering, microscopy and high-resolution techniques, which have [43] The initial distributions of monomer and total protein( left side) influencest he endpoint scalingl aws(rights ide). The correspondence between the initial and finals tages is direct if (a) no oligomerization pathway is presento r( b) oligomerization is irreversible, and indirect if (c) oligomerization isf ully reversible. Green lines describe cases of protein solubility values C* ¼ 0( solid lines) and C* > 0( dashed lines). [43] assuming the cases of predominant secondaryn ucleationa nd hyperbolic initial distributions of monomersvs. total protein.
been subjecto fu pdated reviews by for example, Poklar Ulrih, [45] Pryore tal., [46] and Renaud et al.. [47] The applicationo f these techniques may either confirm or deny the first indications resulting from the amyloid aggregation assay.I llustrating this, Wobst et al. [48] employed circulard ichroism (CD) to detect changes in the secondary structure of tau protein and to confirm that the green tea polyphenol (À)-epigallocatechin gallate (EGCG)p revents the formation of b-sheet-rich tau oligomers. On the other hand, Middleton et al. [49] used isotope labelling and two-dimensional infrared spectroscopy to show how aggregation inhibitors may functionb yc omplex structural processes that are not detected by ThT fluorescence. Infrared nanospectroscopy has recentlyb een used to characterize oligomeric andf ibrillars pecies during amyloidf ormation of ataxin-3. [50] Nuclear Magnetic Resonance (NMR) spectroscopy can provide high-resolutions tructural information as that used to unveilt he ligand bindingd etails of an anti-amyloidogenic compound (phthalocyanine tetrasulfonate) to a-synuclein. Alternatively,N MR spectroscopy can be utilized to follow the formation of intermediate and off-pathwayo ligomers by periodically collecting the 1 HNMR spectra associatedt om onomer depletion. This has been done whiles tudying the effect of Cu 2 + on a-synuclein aggregation, [51] and to demonstrate the ability of EGCG to shifto ff-pathway aggregation of Ab40. [52] Solidstate NMR, [53] together with X-ray microcrystallography, [54] X-ray fiber diffraction [55] and cryo-electron microscopy [56] furthere nlarged the resolution limits of amyloid structures, [57] and contributedt or eveal morphological differences between amyloid fibrils generated in vitro or in the brain. [58] With the recenta dvancesi ni nstrumentation, high intensity synchrotron sources, robotics/automation, speed of data processing, etc.,s ome of the benchmark technologies are now being applied in de novo screenings of aggregation modulators. For example, inhibitors of human IAPP and Ab40 aggregation were identified by ion mobility spectrometry-mass spectrometry using ThT fluorescencem onitoring as ac ontrol method to detect possible hydrophobic interactions that becomel ost in the gas phase. [59] The scope of light scattering techniques is also expanding from proof-of-concept to high-throughput applications as in the cases of dynamic light scattering (DLS) for size distribution monitoring, [60] and small angle X-ray scattering (SAXS) for characterizingt he oligomeric equilibrium of non-aggregatedsamples. [61] In another approach, atime-resolvedf luorescence resonance energy transfer (FRET)a ssay was developed to screen 7:46 Â 10 5 compounds and identify 56 hits that markedly inhibit a-synucleina nd severalp henyl-benzoxazol compounds that promote a-synuclein aggregation (proaggregators). [62] Important for subsequentp hases of hit to lead optimization, [5, 18] cell-based assays based on phenotypica nd cytotoxicity readouts have also been used for compound screening purposes in the identification of IAAP aggregation inhibitors. [63] 
Conclusions and Perspectives
Despite all the advances in the understanding of protein aggregation kinetics, the translation of this knowledge into new practical tools for drug discoveryh as been limited. We believe that this scenario is about to change on account of twor easons both connected with the key role played by soluble oligomers in the process of amyloid fibril formation. First, there is a growinginterest in anti-oligomerization compounds as apossible therapeutic strategy to block the progression of neurodegeneratived isorders and amyloidoses. Second, soluble oligomers, andp articularly non-amyloidogenic off-pathwayo ligomers leave distinctive signatures in amyloid aggregation curves and scalingl aws that help distinguishing which type of protein aggregates are being targeted. In the present work we reviewed the different mechanisms of action of known antiamyloid and anti-olgomerization compounds and showedh ow their effect can be identified in reactionp rogress curves. The systematization of this analysis led us to proposet he 3-point aggregation assay for the primary screening of large libraries of chemical compounds based on ThT fluorescence readouts at the starting-point, (supposed) half-life and (supposed) endpoint instants of the reaction. We also reviewed the chemical kinetic tools availablef or the secondary screening and hit validation phases,w hich may involve the analysis of full progress curves represented in modified coordinates and the analysiso f DF F , v 50 ,and t 50 scaling laws.
